Inhibikase Therapeutics, Inc. (IKT) Tops Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) reported Q3 EPS of ($0.86), $0.01 better than the analyst estimate of ($0.87).
For earnings history and earnings-related data on Inhibikase Therapeutics, Inc. (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Mining said to delay IPO of American gold business to 2027
- Tilly's, Inc. (TLYS) Tops Q2 EPS by 10c, Beats on Revenue
- C3.ai (AI) Tops Q1 EPS by 5c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
